Niagen Bioscience (NAGE) Research & Development (2010 - 2026)

Niagen Bioscience (NAGE) has reported Research & Development for 17 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 17.73% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $6.6 million (down 64.26% YoY), while the FY2025 annual figure was $6.3 million, down 78.52% from the prior year.
• Research & Development retreated to $1.5 million in Q1 2026 per NAGE's latest filing, from $1.7 million in the prior quarter.
• Across five years, Research & Development topped out at $24.8 million in Q4 2022 and bottomed at $1.2 million in Q1 2023.
• Historically, Research & Development has averaged $5.5 million across 5 years, with a median of $1.7 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development surged 946.63% — and 2023, when it sank 85.52%.
• Niagen Bioscience's Research & Development stood at $24.8 million in 2022, then declined by 8.59% to $22.6 million in 2023, then slumped by 61.5% to $8.7 million in 2024, then slumped by 80.38% to $1.7 million in 2025, then decreased by 13.39% to $1.5 million in 2026.
• Business Quant data shows NAGE's Research & Development at $1.5 million in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.